Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Celgene receives patent for SelCID

Aug. 21, 1997

Boston Life Sciences completes phase III trial of Therafectin

Aug. 20, 1997

Salagen approved for Sjogren's syndrome in Canada

Aug. 20, 1997

New treatment for osteoarthritis approved for marketing in U.S.

Aug. 18, 1997

Antiinflammatory drugs in early development at Searle

Aug. 13, 1997

MMP/TNF-alpha inhibitors from Novartis

Aug. 12, 1997

Amarillo Biosciences completes enrollment for phase II study on Sjogren's syndrome

Aug. 12, 1997

Cephalon reports cysteine/serine protease inhibitors with broad therapeutic potential

Aug. 11, 1997

Antiarthritic activity of British Biotech MMP/TNF-alpha inhibitors

Aug. 8, 1997

Nabumetone shows superior safety profile in comparative study

Aug. 6, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...